CAS: 887919-35-9; Bis(Di-Tert-Butyl(4-Dimethylaminophenyl)Phosphine)Dichloropalladium(Ii)

上下游产品

dichloro(1,5-cyclo°Ctadiene)palladium(II) (4-(N,N-dimethylamino)phenyl)-di-tert-butylphosphine dichloro bis(acetonitrile) palladium(II) 4-N,N-dimethylaminophenyl magnesium chloride

4-(N,N-二甲基)苯胺溴化镁置于copper Bromide体系中,用 四氢呋喃 作为反应溶剂,化学反应 10.13H,反应生成 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II)
参考文献:一种二氯二叔丁基-4-二甲基氨基苯基膦钯的制备方法
标题:一种二氯二叔丁基-4-二甲基氨基苯基膦钯的制备方法
摘要:本发明公开的二氯二叔丁基‑4‑二甲基氨基苯基膦钯的制备方法,包括以下步骤:步骤1,使用原料n,N‑二甲基对卤苯胺与镁屑制备格氏试剂;步骤2,取格氏试剂并降温,随后加入催化剂后反应,再滴加二叔丁基氯化磷,升温后反应即得到二叔丁基‑4‑二甲氨基苯基膦;步骤3,对二叔丁基‑4‑二甲氨基苯基膦纯化处理;步骤4,取双(乙腈)二氯化钯与纯化后的二叔丁基‑4‑二甲氨基苯基膦进行络合反应,即得到目标产物.本发明的制备方法通过对二叔丁基‑4‑二甲氨基苯基膦进行纯化处理,用高纯度的二叔丁基‑4‑二甲氨基苯基膦与双(乙腈)二氯化钯反应,大大降低了贵金属钯的收率损失,使制备成本大幅降低,有很好的实用价值.

专利信息

专利号:US-2023183246-A1
优先权日:2020-05-19
标题 :Continuous flow sonogashira coupling synthesis method
发明人：THOMPSON DAVID HARLEY; SINTIM HERMAN O; QI QINGQING; BIYANI SHRUTI
权利人:PURDUE RESEARCH FOUNDATION
摘要:The present disclosure relates to a telescoped continuous flow Sonogashira coupling synthesis for some lead compounds to support in vivo studies and pre-clinical evaluation. The application of high throughput tools combined with the telescoped continuous synthesis method can enable an efficient and safe synthesis of compounds of interest involving hazardous coupling reagents such as HATU, while minimizing by-product formation.

专利号:US-12049470-B2
优先权日:2021-02-01
标 题 :MK2 inhibitors, the synthesis thereof, and intermediates thereto
发明人：RUCHELMAN ALEXANDER L; COOMBS JOHN R; ZHU KEMING; LIM DANIEL; JOE CANDICE LEE; GEORGE DAVID T; ZHENG BIN; LIN DONG
权利人:CELGENE CORP
摘要:The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.

专利号:WO-2023086801-A1
优先权日:2021-11-09
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-2024010638-A1
优先权日:2020-11-13
标题:Improved synthesis of crac channel inhibitors
发明人：STAUDERMAN KENNETH; DUNN MICHAEL; OLMSTEAD KAY
权利人:CALCIMEDICA INC
摘要:Provided herein is an improved synthetic method for the production of CRAC channel inhibitors. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.

专利号:US-11512097-B2
优先权日:2019-11-25
标题 :Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
发明人：ALLEN JENNIFER R; BELTRANI MICHELA; BOURBEAU MATTHEW P; DAMYANOVA TEODORA P; LINGARD IAIN; MINATTI ANA E; VINCETTI PAOLO
权利人:AMGEN INC
摘要:The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5Dâ€?). The compounds have a general Formula I n nwherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.